

Supplementary Table 5. Treatment after discontinuation of study drug

After treatment with study drug	Regorafenib (n=102)	Nivolumab (n=48)	P-value
Systemic therapy	27 (26.5)	14 (29.2)	0.73
Regorafenib	–	9 (18.8)	
Nivolumab	27 (26.5)	–	
Lenvatinib	0	1 (2.1)	
Cytotoxic chemotherapy	0	5 (10.4)	
Transarterial chemoembolization	2 (2.0)	7 (14.6)	0.01
Radiotherapy	5 (4.9)	2 (4.2)	1.0
Best supportive care	71 (69.6)	31 (64.6)	0.54
Any treatment after discontinuation of study drug	31 (30.4)	17 (35.4)	0.54

Values are presented as number (%) of patients.